NCT00445510已完成2 期
A Double Blind, Placebo Controlled, Repeat Dose Study to Determine the Effect of GSK256066 87.5 Mcg to Protect Against AMP Challenge in the Lung in Mild Steroid-naive Asthmatics.
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 2
- 主要终点
- AMP PC20: GSK256066 7 days of 87.5mcg vs placebo 2hrs post-dose on Day 7.
研究概览
简要总结
This will be a single centre, randomised, double-blind, placebo-controlled, 2-period crossover study to investigate the effect of treatment with repeat inhaled doses of GSK256066 on bronchial hyper-reactivity to adenosine monophosphate.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
AMP PC20: GSK256066 7 days of 87.5mcg vs placebo 2hrs post-dose on Day 7.
次要结局
- AMP PC20: GSK256066 7 days of 87.5mcg vs placebo 24hrs post-dose on Day 7. Exhaled Nitric Oxide: GSK256066 7 days of 87.5mcg vs placebo at Day 1; 1hr and 2hr, Day 7; 1hr, 2hr and 24hr.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Drug Interaction Study to Investigate Co-administration of GW642444M With KetoconazolePulmonary Disease, Chronic ObstructiveNCT00866515GlaxoSmithKline20
已完成
2 期
Evaluation of the Effect of Pramlintide on Satiety and Food IntakeDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1NCT00042601AstraZeneca51
已完成
1 期
Study Comparing TPI-120 and Neulasta Administered Through Subcutaneous Route in Healthy Adult SubjectsHealthy VolunteersNCT03206229Adello Biologics, LLC120
已完成
1 期
A Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White SubjectsHealthy VolunteersNCT02039089Eisai Inc.32
已完成
1 期
A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 DiabetesType2diabetesEndothelial DysfunctionNCT05831644Vicore Pharma AB11